RE:RE:RE:PanCan's Precision Promise adaptive clinical trial programOncolytics will allocate the additional $5 million Therapeutic Accelerator Award (TAA) funds to ongoing research focused on a clinical trial with pelareorep in combination with modified Folfirinox chemotherapy with or without an immune checkpoint inhibitor.